Hyperhomocysteinemia: A risk factor for arterial and venous thrombotic disease

International Journal of Clinical and Laboratory Research

Volumn 27, Issue 2, 1997, Pages 139-144

  Cattaneo, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Diet; Homocysteine; Thrombosis; Vitamins

Indexed keywords

EID: 0030841487     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02912449     Document Type: Review

References (48)

1. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531.
2. Mudd SH, Levy HL, Skovby F. Disorders of transulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Stanbury JB, Wyngarden JB, Fredrickson DS (eds.) The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 1995: 1279-1327.
3. Rees MW, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337.
4. Kang S-S, Zhou J, Wong PWK, Kowalisyn J, Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988; 43: 414.
5. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJH, Heijer M den, Kluijtmans LAJ, Heuvel LP van den, Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111.
6. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410.
7. Guttormsen AB, Ueland PM, Nesthus I, Nygård O, Schneede J, Vollset SE, Refsum H. Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (≥40 μmol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996; 98: 2174.
8. Nygård O, Vollset SE, Refsum E, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvåle G. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA 1995; 274: 1526.
9. Selhub J, Jaques PF, Wilson PWF, Rush D, Rosenberg JH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270: 2693.
10. Joosten E, Berg A van den, Riezler R, Naurath HJ, Lindenbaum J, Stabler SP, Allen RH. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993; 58: 468.
11. Selhub J, Jaques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaeffer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286.
12. McCully HS. Homocysteine and vascular disease. Nature Med 1996; 2: 386.
13. Ubbink JB, Merwe A van der, Delport R, Allen RH, Stabler SP, Riezler R, Vermaak WJH. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996; 98: 177.
14. Boers GHJ, Fowler B, Smals AGH, et al. Improved identification of heterozygotes for homocystinuria due to cystathionine synthase deficiency by the combination of methionine loading and enzyme determination in cultured fibroblasts. Hum Genet 1985; 69: 164.
15. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of atherosclerosis. Am J Pathol 1969; 56: 111.
16. Malinow MR. Plasma homocyst(e)ine: a risk factor for arterial occlusive diseases. J Nutr 1996; 126: 1238S.
17. Wilcken DEL, Wilcken B. Role of plasma homocyst(e)ine in arterial occlusive diseases. Clin Chem 1994; 40: 857.
18. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in U.S. physicians. JAMA 1992; 268: 877.
19. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395.
20. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis in Communities (ARIC) Study. Circulation 1993; 87: 1107.
21. Robinson K, Mayer EL, Miller DP, Green R, Lente F van, Gupta A, Kattke-Marchant K, Savon SR, Selhub J, Nissen SE, Kutner M, Topol EJ, Jacobsen DW. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92: 2825.
22. Kluijtmans LAJ, Heuvel LPWJ van den, Boers GHJ, Frosst P, Stevens EMB, Oost BA van, Heijer M den, Trijbels FJM, Rozen R, Blom HJ. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35.
23. Mudd SH, Havlik R, Levy HL, McKusick VA, Feinleib M. A study of cardiovascular risk in heterozygotes for homocystinuria Am J Hum Genet 1981; 33: 883.
24. Falcon CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080.
25. Fermo I, Viganò D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995; 123: 747.
26. Heijer M den, Blom HJ, Gerrits WBJ, Rosendaal FR, Haak HL, Wijermans PW, Bos GMJ. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995; 345: 882.
27. Heijer M den, Koster T, Blom HJ, Bos GMJ, Briët E, Reitsma PH, Vanderbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759.
28. Cattaneo M, Martinelli I, Mannucci PM. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 335: 974.
29. Martinelli I, Cattaneo M, Panzeri D, Taioli E, Mannucci PM. Risk factors for primary deep vein thrombosis of the upper extremities. Ann Intern Med. In press.
30. Monzani ML, Cattaneo M, Falcon CR, Martinelli I, Faioni E, Braga M, Mannucci PM. Association between activated protein C resistance and hyperhomocysteinemia in juvenile venous thromboembolism. Thromb Haemost 1995; 73: 1368.
31. Ridker PM, Miletich JP, Hennekens CH, Stampfer MJ. Plasma homocysteine levels, factor V Leiden, and risks of future venous thromboembolism. Circulation 1996; 94: 696.
32. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jackobs C, Fowler B, Seligsohn U. Coexistence of hereditary homocystinuria and factor V Leiden - effect on thrombosis. N Engl J Med 1996; 334: 763.
33. Arruda VR, Zuben PM von, Chiaparini LC, Annichino-Bizzacchi JM, Costa FF. The mutation ALA677 → VAL in the methylene-tetrahydrofolate reductase gene: a risk factor for premature arterial disease and venous thrombosis. Blood 1996; 10 [Suppl 1]: 285 a.
34. Trillot N, Preudhomme C, Alhenc-Gelas M, Gaveriaux V, Bauters A, Gandrille S, Aiach M, Jude B. Thermolabile methylene tetrahydrofolate reductase (MTHFR) does not modify the risk for venous thromboembolism in subjects with heterozygous factor V Leiden. Blood 1996; 10 [Suppl 1]: 284 a.
35. Cattaneo M, Tsai MY, Bucciarelli P, Taioli E, Zighetti ML, Bignell M, Mannucci PM. A common mutation in the methylene-tetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V: Q506). Blood 1996; 10 [Suppl 1]: 285 a.
36. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049.
37. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731.
38. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370.
39. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993; 91: 2873.
40. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308.
41. Wang J, Dudman NPB, Wilcken DEL. Effects of homocysteine and related compounds on prostacyclin production by cultured human vascular endothelial cells. Thromb Haemost 1993; 70: 1047
42. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327.
43. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993; 92: 1381.
44. Broekman MJ, Haijar KA, Marcus AJ, Lev E, Islam N, Safier LB, Fliessbach J. Homocysteine inhibits ecto-ADPase activity of human umbilical vein endothelial cells (abstract). Blood 1994; 84 [Suppl 1]: 77.
45. Tsai J-C, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369.
46. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocysteinemia. J Clin Invest 1996; 98: 24.
47. Cattaneo M, Martinelli I, Faioni E, Franchi F, Zighetti ML, Mannucci PM. High plasma concentrations of activated protein C in patients with deep vein thrombosis and hyperhomocysteinemia. Br J Haematol 1996; 93 [Suppl 2]: 8.
48. Brattström L. Vitamins as homocysteine-lowering agents. J Nutr 1996; 126: 1276S.